By Colin Kellaher
BridgeBio Pharma Inc. on Thursday said it plans to evaluate its BBP-398 small-molecular inhibitor in combination with Amgen Inc.'s cancer drug Lumakras in patients with advanced solid tumors with the KRAS G12C mutation.
BridgeBio, a Palo Alto, Calif., biopharmaceutical company, said it will sponsor a Phase 1/2 study designed to evaluate the safety, tolerability and preliminary efficacy of the combination, while Amgen will provide a supply of Lumakras.
KRAS mutations occur in roughly 17% of malignant solid tumors. The U.S. Food and Drug Administration last year approved Lumakras as the first targeted treatment for patients with KRAS G12C-mutated locally advanced or metastatic nonsmall-cell lung cancer.
BridgeBio's BBP-398 is an inhibitor of SHP2, an oncoprotein overexpressed in a variety of cancer cell types inhibitor. The company is currently advancing a Phase 1 study of BBP-398 in patients with solid tumors driven by mutations in the MAPK signaling pathway, including RAS and receptor tyrosine kinase genes.
BridgeBio last year agreed to collaborate with Bristol Myers Squibb Co. to evaluate the combination of BBP-398 with Bristol's blockbuster cancer drug Opdivo in patients with advanced solid tumors with KRAS mutations.
Write to Colin Kellaher at firstname.lastname@example.org
(END) Dow Jones Newswires